Amyloid transthyretin cardiomyopathy: the importance of early intervention to improve prognosis.

Abstract

The article “Transthyretin Amyloid Cardiomyopathy: clinical features and staging, indications for treatment and mortality” describes the clinical characteristics of 32 patients diagnosed non-invasively with transthyretin amyloid cardiomyopathy (ATTR-CM). Most patients had wild-type ATTR-CM and presented with New York Heart Association (NYHA) functional class II symptoms, preserved left ventricular ejection fraction, and typical cardiac magnetic resonance findings associated with the disease. Atrial fibrillation was present in 50% of the patients, while 25% had moderate or severe aortic stenosis. The NAC staging system was used in these patients to establish prognosis, with 75% of patients were classified as stage I. Notably, only 25% of patients received the transthyretin stabilizer tafamidis, and most of those who died had not received disease-modi- fying therapy.